IO Biotech Reports 2024 Business Highlights
Provided By GlobeNewswire
Last update: Mar 4, 2025
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported business highlights for the fourth quarter of 2024.
Read more at globenewswire.com
